Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	3.26 -	14.92 357.11%	67.58 353.06%	66.61 1.43%	1.18 98.22%	2.92 146.36%
company equity multiplier	3.30 -	1.34 59.40%	1.13 15.76%	1.12 0.39%	-2.07 284.24%	-1.33 35.62%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.20 -	1.01 16.09%	1.00 0.59%	0.99 0.59%	1.12 12.27%	1.05 5.88%
effective tax rate		-0.01 -	-0.00 97.15%	-0.00 1,391.58%	-0.10 3,775.00%
enterprise value multiple	-12.97 -	-11.80 9.06%	-1.50 87.29%	0.30 120.00%	-0.40 232.81%	-0.67 67.45%
fixed asset turnover
free cash flow per share	-19.45 -	-24.87 27.90%	-50.50 103.02%	-58.37 15.60%	-52.57 9.94%	-19.53 62.86%
gross profit margin
interest coverage	-5.03 -	-164.68 3,175.99%	-5.82K 3,432.36%	-2.11K 63.74%	-186.87 91.14%	10.77 105.76%
inventory turnover
long term debt to capitalization					-3.39 -	-0.11 96.72%
net income per ebt	1 -	1.01 0.60%	1.00 0.58%	1.00 0.24%	1.10 9.65%	1 9.04%
net profit margin
operating cash flow per share	-18.28 -	-22.53 23.25%	-40.79 81.04%	-53.39 30.89%	-43.61 18.33%	-19.34 55.66%
operating profit margin
payables turnover
pretax profit margin
price fair value	153.14 -	22.54 85.28%	3.36 85.10%	0.64 80.96%	-0.51 180.07%	-0.10 79.55%
receivables turnover
return on assets	-4.36 -	-1.41 67.54%	-1.50 5.87%	-0.83 44.23%	-3.19 282.16%	-1.72 46.04%
return on capital employed	-12.00 -	-1.87 84.39%	-1.69 9.76%	-0.94 44.24%	23.65 2,610.22%	2.43 89.73%
return on equity	-14.38 -	-1.90 86.82%	-1.69 10.82%	-0.94 44.44%	6.61 804.11%	2.30 65.26%
total debt to capitalization			0.04 -	0.02 58.63%	2.59 15,717.19%	2.42 6.49%

NASDAQ:KRBP

Kiromic BioPharma, Inc.

Last Close

3.08

17/05 16:41

Market Cap

1.89M

Beta: 0.16

Volume Today

11.56K

Avg: 281.88K

PE Ratio

−0.08

PFCF: −0.10